{{#unlinkedwikibase:id=Q417317}}
 Toujeo branded insulin glargine | |
| Clinical data | |
|---|---|
| Trade names | Lantus, Toujeo, Abasaglar, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a600027 |
| License data |
|
| Routes of administration | Subcutaneous |
| Drug class | Insulin (long acting)[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | ~1 hours[1] |
| Duration of action | 24 to 36 hours[1] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C267H404N72O78S6 |
| Molar mass | 6063 g·mol−1 |
  (what is this?) (verify) | |
Insulin glargine, marketed under the names Lantus among others, is a long-acting insulin, used in the management of type I and type II diabetes.[1] It is typically the recommended long acting insulin in the United Kingdom.[4] It is used once a day as an injection just under the skin.[1] Effects generally begin an hour after use.[1]
Common side effects include low blood sugar, problems at the site of injection, itchiness, and weight gain.[1] Other serious side effects include low blood potassium.[1] NPH insulin rather than insulin glargine is generally preferred in pregnancy.[4] After injection microcrystals slowly release insulin for about 24 hours.[1] This insulin causes body tissues to absorb glucose from the blood and decreases glucose production by the liver.[1]
Insulin glargine was approved for medical use in the United States in 2000.[1] It is on the World Health Organization's List of Essential Medicines.[5] In the United States the wholesale cost per 100 units is about US$26 as of 2018.[6] In the United Kingdom this amount costs the NHS about £2.35.[4] In 2017, it was the 33rd most commonly prescribed medication in the United States with more than 20 million prescriptions.[7][8]
References edit
- ^ a b c d e f g h i j k l m "Insulin Glargine Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 5 December 2020. Retrieved 23 December 2018.
- ^ "Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 9 January 2021. Retrieved 7 May 2020.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 25 February 2021. Retrieved 9 September 2020.
- ^ a b c British national formulary: BNF 76 (76th ed.). Pharmaceutical Press. 2018. p. 701. ISBN 9780857113382.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services. Archived from the original on 2018-12-19. Retrieved 22 December 2018.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Insulin Glargine - Drug Usage Statistics". ClinCalc. 23 December 2019. Archived from the original on 29 November 2020. Retrieved 11 April 2020.